A Phase 1 Single-Dose Escalation Study of PF-04308515 in Healthy Volunteers

• Drug: PF-04308515
  
  Oral solution/suspension 0.1 mg up to potentially 350 mg QD at a single dose.
• Drug: Placebo
  
  Placebo solution/suspension to match active drug QD at a single dose.

• Experimental: PF-04308515
  
  Intervention: Drug: PF-04308515
• Placebo Comparator: Placebo
  
  Intervention: Drug: Placebo

Inclusion Criteria:

• Healthy males between 18 and 55 years, inclusive
• Healthy females between 18 and 44 years, inclusive.
• Women need to be surgically sterile

Exclusion Criteria:

• Evidence or history of clinically significant disease
• Post-menopausal women
• History of intolerance or significant adverse effects with glucocorticoids